Press "Enter" to skip to content

Halucenex Expanded Phase II Psilocybin Experiment to Embrace Non-Veterans with PTSD

Halucenex Life Sciences, a Creso Pharma (ASX: CPH) acquisition target in Canada, has increased the enrollment of phase II clinical study of the psychedelic psilocybin to include non-veterans treatment-resistant post-traumatic stress disorder (PTSD).The study’s original goal was to see if psilocybin (the active ingredient in magic mushrooms) may help veterans and first responders who have treatment-resistant PTSD.

Creso’s decision to accept non-veterans comes after Halucenex received an “overwhelming” number of inquiries from members of the general public suffering from chronic mental health disorders and seeking alternative therapies.The addition of non-veterans to the experiment, according to the business, will allow it to collect an extra data set, allowing it to provide real-world instances of psilocybin’s success when utilized as an alternate treatment method.

The trial results will be used to advance discussions with potential partners, such as drug developers and large pharmaceutical companies, as well as insurance providers and regulatory bodies, to further cement Halucenex position as a first mover in the emerging psychedelic medicines space.Non-veteran volunteers, according to Halucenex CEO Bill Fleming, will benefit from the experiment in a variety of ways.

“Following different legal reforms in the United States, as well as the worsening effects of COVID-19 on mental health disorders across the community, it is becoming increasingly clear that psychedelic therapies might become ordinary in the near future,” he stated.”Including regular individuals in our research and development will offer us with instances of how psilocybin might be used to treat mental health concerns more broadly.”According to Creso non-executive chairman Adam Blumenthal, the enlarged study would help Halucenex become a “best-in-class service.””Halucenex management team continues to work on developing psychedelic chemicals and therapies for veterans and first responders, as well as regular people,” he stated.

Be First to Comment

Leave a Reply

Your email address will not be published.